Vir Biotechnology, Inc. is planning to go it alone or work with new partners to advance next-generation therapies for COVID-19 and other potential coronavirus outbreaks after GSK plc decided that its research priorities lie elsewhere.
The San Francisco-based biotech has revealed that its research collaboration agreement







